D. Ricci

发表

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

H. Scher, E. Antonarakis, C. Higano, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.

D. Fife, Xiaodong Wu, Nadine Cohen, 2008, Pharmacogenomics.

Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.

A. Wyatt, B. Tombal, C. Sternberg, 2019, JCO precision oncology.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

P. Neven, M. Campone, D. Hayes, 2016, Clinical Cancer Research.

Global Requirements for DNA Sample Collections: Results of a Survey of 204 Ethics Committees in 40 Countries

A. Snapir, D. Ricci, E. Broderick, 2011, Clinical pharmacology and therapeutics.

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer

F. Saad, B. Hadaschik, F. Feng, 2021, JAMA oncology.

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial.

B. Tombal, C. Sternberg, A. Merseburger, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.

P. Troncoso, John W. Davis, C. Logothetis, 2019, European urology.

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

F. Saad, H. Scher, D. George, 2019, Annals of Oncology.

Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.

A. Wyatt, N. Agarwal, F. Feng, 2020 .

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

H. Scher, D. George, E. Yu, 2019, Journal of Clinical Oncology.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.

Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts

P. Nelson, R. Vessella, E. Corey, 2016, Clinical Cancer Research.

Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease

A. Wyatt, F. Feng, E. Small, 2021, Clinical Cancer Research.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Eugene Zhu, Shalini Chaturvedi, H. Eom, 2015, Blood.

Patients and Methods: a Candidate Array Was Designed Based on the Breast Cancer Information Core Database For

B. Monk, R. Favis, P. Ghatage, 2022 .

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

H. Scher, C. Logothetis, D. Rathkopf, 2015, Clinical Cancer Research.

PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE

F. Saad, B. Hadaschik, F. Feng, 2019, Journal of Urology.

Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study

F. Feng, E. Small, P. Mainwaring, 2018, Clinical Research (Excluding Clinical Trials).

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

P. Sonneveld, R. Favis, R. Orlowski, 2010, Annals of Hematology.

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.

B. Monk, S. Kaye, C. Lebedinsky, 2011, Gynecologic oncology.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementation of Pharmacogenomic Sample Collection in Clinical Trials

D. Ricci, M. Franc, 2008 .

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

D. Esseltine, H. Goldschmidt, M. Dimopoulos, 2011, European journal of haematology.

Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.

F. Saad, B. Hadaschik, F. Feng, 2019, Journal of Clinical Oncology.

Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa.

P. Troncoso, John W. Davis, C. Logothetis, 2015 .

Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

A. Wyatt, N. Agarwal, F. Feng, 2019, Annals of Oncology.

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

F. Saad, H. Scher, D. George, 2020 .

Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302.

J. Carles, H. Scher, J. Bono, 2014 .

Genetic variation associated with bortezomib-induced peripheral neuropathy

G. Mulligan, P. Richardson, R. Favis, 2011, Pharmacogenetics and genomics.

Abstract P5-01-09: Identification of Molecular Apocrine Triple Negative Breast Cancer Using a Novel 2-Gene Assay and Comparison with Androgen Receptor Protein Expression and Gene Expression Profiling by DASL

J. Wong, J. Alvarez, S. Platero, 2012 .

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

B. Monk, R. Favis, P. Ghatage, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

E. Small, D. Rathkopf, D. Olmos, 2019, Annals of Oncology.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

P. Neven, M. Campone, D. Hayes, 2014 .

Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study

K. Fizazi, M. Gormley, K. Chi, 2019, Annals of Oncology.